Vesatolimod - Gilead Sciences
Alternative Names: GS-9620Latest Information Update: 09 May 2025
At a glance
- Originator Gilead Sciences
- Developer Aelix Therapeutics; Gilead Sciences; National Institute of Allergy and Infectious Diseases
- Class Amines; Antiretrovirals; Antivirals; Ethers; Pteridines; Pyrrolidines; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 25 Apr 2025 National Institute of Allergy and Infectious Diseases in collaboration with Gilead Sciences suspends a phase I/II trial in HIV 1 infection (Combination therapy,Treatment-experienced) in US and Brazil (NCT06071767)
- 12 Mar 2025 Adverse events data from a phase IIa trial in HIV 1 infections released by Gilead Sciences
- 16 Jan 2025 Gilead Sciences completes phase II FRESH trial in HIV-1 infections in South Africa (IV) (NCT05281510)